Imugene (ASX:IMU) report PD1-Vaxx generates high levels of antibodies

Company News

by Rachael Jones

Immuno-therapy company Imugene (ASX:IMU) report that studies have shown their PD1-Vaxx cancer immunotherapy drug generates high levels of antibodies.

They will start trials with for patients with non-small cell lung cancer.

This the most common type of lung cancer, accounting for around 80 per cent of cases.

Imugene’s MD and CEO, Leslie Chong says the phase 1 trails in 2020 are a an important next step in bringing much needed new therapeutic option to cancer patients.

Shares in Imugene (ASX:IMU) are trading 2.9 per cent higher at $0.04.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.